TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03951116
Drug: FCN-437
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
Study: NCT02156336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, BID; for a maximum of 51 days.
Study: NCT03246659
Drug: 111In-CP04 with co-administration of gelofusine/gelaspan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
Study: NCT02327273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00344006
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04302649
Drug: peritoneal dialysate at 37°C temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
Study: NCT00113269
Drug: steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and/or oral
Study: NCT01988298
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg each 8 hours
Study: NCT01988298
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group
Study: NCT01268124
Drug: HTC-867
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00547053
Drug: Amiloride Solution for Inhalation
Normalized name: amiloride Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
Study: NCT04426084
Drug: Antihypertensive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date.~Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls
Study: NCT04426084
Drug: Statins (Cardiovascular Agents)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.
Study: NCT00605995
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
Study: NCT01171183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00835510
Drug: Lotrimin Ultra (butenafine) 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment applied to affected area twice daily for 7 days
Study: NCT00350701
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02151357
Drug: DCBCI0901
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
Study: NCT00130507
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01765296
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg capsule
Study: NCT01765296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
Study: NCT01619852
Drug: .9 normal saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
Study: NCT01619852
Drug: Group L (lidocaine)
Normalized name: lidocaine hydrochloride Injectable Solution [L-Caine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
Study: NCT00970489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive Oil capsules
Study: NCT00394186
Drug: GW427353
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00394186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00514488
Drug: STI571 (400 mg/day; or 800 mg/day)
Normalized name: clear days ahead Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03090971
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
Study: NCT02331810
Drug: SAR113244
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT02331810
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT04780984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03416569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo skin patch + placebo capsule
Study: NCT00489528
Drug: Somatropin; Recombinant human growth hormone (r hGH)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01011699
Drug: nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week).
Study: NCT04338906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instead of Camostat Mesilate, tid, d1-d7
Study: NCT01159223
Drug: ATV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
Study: NCT02289989
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
Study: NCT00548067
Drug: Valsartan/hydrochlorothiazide (HCTZ)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02424019
Drug: ILUVIEN 0.19 MG
Normalized name: Iluvien 0.19 MG Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02235701
Drug: 170 mg/m2 aldoxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
Study: NCT02235701
Drug: 250 mg/m2 aldoxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
Study: NCT01597505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
Study: NCT00624715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
Study: NCT03716622
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bismuth-clarithromycin-containing quadruple regimens
Study: NCT00185510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days a week Vehicle (Advabase)
Study: NCT01967264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT04000932
Drug: Local steroid injection-Diprospan ®, Schering Plough
Approvals — FDA: no, EMA: no, PMDA: no
Description: The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
Study: NCT04658186
Drug: UCB0599
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
Study: NCT00006656
Drug: carmustine in ethanol
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04658186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
Study: NCT01955759
Drug: rosuvastatin 20 mg tab x1
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: starting 7 days before coronary by-pass surgery
Study: NCT00384865
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg, taken orally, once a day for 6 months
Study: NCT03216902
Drug: Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
Study: NCT02960945
Drug: CTP-543, 16 mg (2 x 8 mg tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00867178
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00852670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered orally once daily
Study: NCT01452737
Drug: Standard Bowel Prep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to take 4L of Golytely the day prior to procedure.
Study: NCT00994773
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily doses for 14 days
Study: NCT01522703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfalfa Sprouts
Study: NCT02525081
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 10 mg
Study: NCT04564521
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.
Study: NCT01755546
Drug: EN3409
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
Study: NCT00601003
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
Study: NCT06087562
Drug: 0,9% normal saline 20mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided placebo block with 20mL of 0,9% normal saline
Study: NCT01589562
Drug: DW-ES(B) 625mg/5ml
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 625mg/5ml, Nano suspension, Single dose
Study: NCT02430363
Drug: MK - 3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Intravenously
Study: NCT04234945
Drug: Doxycycline Capsule
Normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
Study: NCT04234945
Drug: Multivitamins W/Iron Tab
Normalized name: MULTIVITAMINS W/IRON TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
Study: NCT00977769
Drug: placebo (NaCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodynamic effect of
Study: NCT02724293
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received placebo
Study: NCT00890539
Drug: Methacholine challenge
Normalized name: Methacholine Challenge Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical and research test used in asthma
Study: NCT01257399
Drug: Asacol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablets
Study: NCT00522509
Drug: Floxuridine FUDR
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00983905
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
Study: NCT00184197
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00280683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets that match the L-arginine intervention tablets will be given for three months
Study: NCT02875834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
Study: NCT00487318
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon/RBV
Study: NCT00487318
Drug: fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add fluvastatin at 20-40 mg/day to standard of care
Study: NCT00489645
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo SC during euglycemia
Study: NCT00489645
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo during hyperglycemia
Study: NCT01812265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose
Study: NCT00863798
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Study: NCT02866071
Drug: Placebo-Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg IN Placebo
Study: NCT03545373
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin tablet taken orally
Study: NCT02941848
Drug: HCP1306
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02019875
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP3A4 and Pgp inhibitor in both intestine and liiver
Study: NCT02188849
Drug: Creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine powder 5 g day
Study: NCT01377792
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug
Study: NCT00591123
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions
Study: NCT04485299
Drug: Bifluorid 10 ,VOCO
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF and CaF 10 %
Study: NCT05229029
Drug: TCM Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.
Study: NCT05229029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs
Study: NCT00549887
Drug: Analog or Human Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: prescribed in accordance with usual clinical practice
Study: NCT01316887
Drug: 125/25 mcg once-daily GSK573719/GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719/GW642444
Study: NCT01316887
Drug: 125mcg once-daily GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719
Study: NCT01316887
Drug: Placebo once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive
Study: NCT01476813
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug versus comparator
Study: NCT03987230
Drug: Sensitive Eyes® Plus Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitive Eyes® Plus Saline Solution
Study: NCT01743521
Drug: TPV/PEG-IFN/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly.
Study: NCT02141958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be used to keep the study double-blind.
Study: NCT02099136
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00664183
Drug: Vitreosolve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT04191148
Drug: LBP-EC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration
Study: NCT04191148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactated Ringers Solution for Injection dosed BID by intraurethral administration
Study: NCT01588366
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03530462
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 monthly for 4-6 cycles depending on the response
Study: NCT03530462
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
Study: NCT00644111
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
Study: NCT01841112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received matching placebo to the BI-409306 (film-coated tablet/s), administered orally on day 1 for single dose (SD) segment and on day 3 to day 9 for multiple dose (MD) segment
Study: NCT01628965
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT01438840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01438840
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.
Study: NCT00025662
Drug: RFT5-SMPT-dgA
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A specific anti-interleukin-2 receptor immunotoxin
Study: NCT00025662
Drug: Isolex system
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34 selection/ T cell depletion used this system
Study: NCT00485550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00963443
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 Sachets of 500 mg Aspirin Complex.
Study: NCT00963443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03498586
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of normal saline as an irrigant for open-irrigated ablation catheters
Study: NCT01470599
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORAL TABLET, TWICE DAILY
Study: NCT01470599
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORAL TABLETS, TWICE DAILY
Study: NCT00004039
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes